Welcome to Dishman Carbogen Amcis Ltd!
We are a global outsourcing partner for pharmaceutical companies, offering a portfolio of products and development, scale-up and manufacturing services. The Dishman Group continually invests in the pharmaceutical industry, ensuring our businesses can provide pharmaceutical customers with high-value, high-quality products and services today and in the future. Our focus is to add value to the global pharmaceutical industry by serving as a reliable partner. We strongly believe that our business is successful only when our customers are successful.
The mission of Dishman Carbogen Amcis Ltd and its fundamental purpose is to offer support and assistance to people across the world suffering from illness and disease, striving to ensure that this is completed efficiently, comprehensively, and effectively.
NEW DELHI, India, (April 18, 2024) – Dishman Carbogen Amcis Ltd received the Choose France-Best Indian Investment in France award by the Indo French Chamber of Commerce & Industry in partnership with Business France India, at the sixth flagship event of the Indo-French Business Awards (IFBA) and Grand Prix VIE, in New Delhi. His Excellency Mr. Thierry Mathou, Ambassador of France presented the award which recognises Dishman’s investment in a new...
Dishman Carbogen Amcis Ltd granted CEP by EDQM and EUDRA GMP Certification by the Italian Medicines Agency
Gujarat, INDIA (January 2024) – Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), a pharmaceutical API manufacturing and drug development company receives the CEP certification by the EDQM and the EUDRA GMP by the Italian...
Gujarat, India - After a successful on-site inspection, Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), receives the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) certification.
DCAL’s drug substances manufacturing facility located in Bavla, underwent an inspection by the Japanese Health Authority. We are glad to announce that the inspection ended satisfactorily, and no major or critical observations...
Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood...
Ahmedabad, India (May 21th, 2021) — India-based Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new study that provides critical insights into the treatment of vitamin D deficiency in obesity and in fat malabsorption syndromes. The research was conducted by Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly-owned...
BUBENDORF, Switzerland (August 17, 2020) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today new expansion plans in Switzerland and France.
CARBOGEN AMCIS announces two major expansion projects that will increase manufacturing capacity to better meet the demands of the current market and its customers. The new facilities, located in Switzerland and France, will...
-
Leader in API , CRAMS, Formulation
Dishman Carbogen Amcis Ltd - A Leader in API, CRAMS, Quats will be showcasing our portfolio and expertise at CPHI Japan 2025
Our team led by Saleem Shaikh, Head - International markets, APIs, Quats, Fine Chemicals, and Mr. Paul Kuad, Sales Manager, are excited to participate in CPhI Japan 2025, a gateway into the Japanese pharmaceuticals and healthcare market. Please click on the Contact Us page for their details.
-
Speaking about his experience at iPHEX 2024 and business prospects, a team spokesperson stated:
“Soft gelatin capsule formulations have a bright future. We have received multiple enquiries for CRAMS opportunities in soft gel capsule formulations. The CRAMS market demand is high due to the scarcity of skilled quality players in this formulation segment. The core strengths of DCAL are its science-based approach towards product development, regulatory-sufficiency documentation with an international standard manufacturing facility, and support staff with in-depth technical knowledge and experience in soft gel capsules technical know-how. Our core development strength is converting very poorly soluble API into soft gel formulation to enhance bioavailability.
As a new entrant in the soft gel capsule formulation business, we keep working towards the diversification of product portfolios in different therapeutic ranges with a scientific approach. With a wide diversified range of products, we want our customers to meet the market needs and demands. At iPHEX, we were proud to connect with overseas buyers and Indian visitors who are familiar with the Dishman brand in the API business. They were very impressed with our venture into the very niche formulation category of soft gelatin capsule dosage forms CRAMS business.”
As part of our commitment to continue the long fight against COVID-19, we have doubled the manufacturing capacity of some of our disinfectant API production facilities. Since March 2020, we have manufactured and globally exported more than 300 metric tons of disinfectant APIs.
© 2023 Dishman Carbogen Amcis Ltd - All Rights Reserved